ALK-Abelló A/S
ALK-B
Rank in Stocks
#2349
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Share Price
$37.79
Market Cap
$8.38B
Change (1 day)
0.00%
Change (1 year)
12.73%
Country
DK
Trade ALK-Abelló A/S (ALK-B)
Category
Healthcare
Number of shares outstanding for ALK-Abelló A/S (ALK-B)
Number of shares outstanding as of June 2026: 221.88M
According to ALK-Abelló A/S latest financial reports and stock price the company's current number of shares outstanding is 221.88M. At the end of December 2023 the company had 221.15M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for ALK-Abelló A/S (ALK-B) from 2004 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 221.88M | 0.25% |
| 2024 | 221.32M | 0.08% |
| 2023 | 221.15M | 0.29% |
| 2022 | 220.50M | 0.51% |
| 2021 | 219.39M | 0.49% |
| 2020 | 218.32M | 0.14% |
| 2019 | 218.01M | 0.31% |
| 2018 | 217.33M | 9.53% |
| 2017 | 198.43M | 1.07% |
| 2016 | 196.33M | 1.15% |
| 2015 | 194.09M | 0.46% |
| 2014 | 193.20M | 0.00% |
| 2013 | 193.20M | -0.87% |
| 2012 | 194.91M | -1.53% |
| 2011 | 197.94M | -0.14% |
| 2010 | 198.22M | -0.49% |
| 2009 | 199.19M | -0.34% |
| 2008 | 199.88M | -0.33% |
| 2007 | 200.53M | -0.74% |
| 2006 | 202.02M | 0.47% |
| 2005 | 201.07M | -0.60% |
| 2004 | 202.28M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 14.43% |
US
|
|
| 396.00M | 78.48% |
US
|
|
| 478.91M | 115.84% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -71.97% |
NL
|
